We are initiating coverage of RXi Pharmaceuticals Corp (RXII) with a $20.00 price target based on our estimates for a 2023 launch of RXI-109 and a 2022 launch of Samcyprone, both through the efforts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback